Companies:
49,811
Total Market Cap:
139341286051154.47
Global Rank
#5021
Country Rank
#21
Market Cap
2.79 B
Price
9.19
Change (%)
2.91%
Volume
202,737
Alvotech's latest marketcap:
2.79 B
As of 07/05/2025, Alvotech's market capitalization has reached $2.79 B. According to our data, Alvotech is the 5021th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.79 B |
| Revenue (ttm) | 587.89 M |
| Net Income (ttm) | 96.54 M |
| Shares Out | 303.47 M |
| EPS (ttm) | 0.34 |
| Forward PE | 27.51 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Alvotech's yearly market capitalization.
Alvotech has seen its market value grow from $327.81 M to $2.79 B since 2020, representing a total increase of 750.76% and an annual compound growth rate (CAGR) of 60.76%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $2.79 B | -30.11% | 5021 |
| 12/31/2024 | $3.99 B | 30.92% | 3525 |
| 12/29/2023 | $3.05 B | 22.59% | 4218 |
| 12/30/2022 | $2.49 B | 705.34% | 4618 |
| 12/31/2021 | $308.75 M | -5.82% | 16298 |
| 12/31/2020 | $327.81 M | 14032 |
Company Profile
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. The company specializes in biosimilar products targeting autoimmune, eye, and bone disorders, as well as cancer.
Key Biosimilar Products
- AVT02 – A high-concentration biosimilar to Humira, treating inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis.
- AVT04 – A biosimilar to Stelara, addressing psoriatic arthritis, ulcerative colitis, and other inflammatory disorders.
- AVT06 – A biosimilar to Eylea, used for age-related macular degeneration, diabetic retinopathy, and macular edema.
- AVT03 – A biosimilar to Xgeva and Prolia, aiding in bone fracture prevention and cancer-related bone conditions.
- AVT05 – A biosimilar to Simponi and Simponi Aria, treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- AVT16 – A biosimilar to Entyvio, targeting moderate to severe ulcerative colitis and Crohn’s disease.
- AVT23 – A biosimilar to Xolair, addressing allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyps.
- AVT33 – A biosimilar to Keytruda, currently in early-phase development.
Founded in 2013, Alvotech is headquartered in Luxembourg, Luxembourg.
Frequently Asked Questions
-
What is Alvotech's (ALVO) current market cap?As of 07/05/2025, Alvotech (including the parent company, if applicable) has an estimated market capitalization of $2.79 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Alvotech (ALVO) rank globally by market cap?Alvotech global market capitalization ranking is approximately 5021 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.